Interested in Cartistem Treatment? On this page, we have collected links for you, where you will receive the most necessary information about Cartistem Treatment.
http://www.medi-post.com/cartistem/
CARTISTEM® – allogeneic umbilical cord blood-derived mesenchymal stem cells, is used for the treatment of knee cartilage defects in patients with Osteoarthritis (with ICRS grade* IV cartilage defect) caused by degeneration or repetitive trauma. *ICRS …
https://www.sciencedaily.com/releases/2013/01/130124163246.htm
Jan 24, 2013 · Cartistem is surgically administered into the area of cartilage damage following an arthroscopic surgery as an adjunct to microfracture, a commonly used technique used to repair cartilage damage.
https://clinicaltrials.gov/ct2/show/NCT04310215
Mar 17, 2020 · Treatment: Official Title: A Multi-center, Single-blind, Randomized, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adding CARTISTEM® on Microfracture in Patients With Talar Chondral or Osteochondral Defect: Actual Study Start Date : March 4, 2020: Estimated Primary Completion Date : December 2021: Estimated Study Completion Date :
https://clinicaltrials.gov/ct2/show/NCT01626677
Jun 25, 2012 · Biological: CARTISTEM Procedure: Microfracture. Phase 3. Detailed Description: This long term follow-up study is performed to assess the long-term safety and efficacy of CARTISTEM®, human umbilical cord blood-derived mesenchymal stem cells, in repair of cartilage injury or defects, compared with microfracture.
http://stemcellsfreak.com/2015/01/cartistem-price.html
What Is Cartistem? CARTISTEM® is a allogeneic stem cell based treatment that is available in South Korea by Dong-A Pharmaceuticals Co., Ltd. It has been approved by the Korean FDA (KFDA) and it has also received US FDA clearance to conduct Phase I/IIa clinical trials in the United States.Estimated Reading Time: 2 mins
https://pubmed.ncbi.nlm.nih.gov/28191757/
The stem cell-based medicinal product (a composite of culture-expanded allogeneic hUCB-MSCs and hyaluronic acid hydrogel [Cartistem]) was applied to the lesion site. Safety was assessed by the World Health Organization common toxicity criteria. The primary efficacy outcome was ICRS cartilage repair assessed by arthroscopy at 12 weeks.
https://link.springer.com/article/10.1007/s00441-019-03069-9
Jul 15, 2019 · Regenerative therapies using mesenchymal stem cells (MSCs) provide an option for OA treatment as it could potentially regenerate the damaged cartilage. Bone marrow, adipose tissue and synovium are common MSC sources.
https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
Second CAR T-Cell Therapy Approved for Lymphoma Tisagenlecleucel is a new option for some patients with common lymphoma. In 2017, two CAR T-cell therapies were approved by the Food and Drug Administration (FDA), one for the treatment of children with acute lymphoblastic leukemia (ALL) and the other for adults with advanced lymphomas.
We hope you have found all the information you need about Cartistem Treatment through the links above.
